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INTRODUCTION
O ne of the hallmarks of cancer genetics is that cancer cells accumulate mutations to escape apoptotic events leading to their malignant growth. 1 these events are the processes of programmed cell death (PcD) that may occur in multicellular organisms. once triggered, PcD involves a series of biochemical events leading to a characteristic cell morphology and death-in more specific terms, a series of biochemical events that lead to a variety of morphological changes, including changes to the cell membrane such as the loss of membrane asymmetry and attachment, cell shrinkage, nuclear fragmentation, and chromosomal Dna fragmentation. 1, 2 PcD is instrumental in maintaining tissue homeostasis by actively eliminating unwanted and mutated cells. it is a highly controlled process triggered by intrinsic or extrinsic stimuli such as Dna damage or cytotoxic agents. Both pathways converge by activating the effector caspases belonging to the group ii class of caspasesnamely, caspases 2, 3, and 7 ( Fig. 1) . given their central role as death effector mediators, activation of group ii caspases ideally reflects progression into apoptosis regardless of the nature of the stimulus and, as such, provides a good opportunity to screen for and discover the next generation of apoptosis-inducing drugs needed to overcome current drug resistance and to improve prognosis in cancer therapy.
in addition to target-based assays that could potentially be adapted to being performed with cells-such as the homogeneous β-galactosidase fragment complementation method for caspase activity 3 -current cell-based assays monitoring apoptosis in microplates that are potentially amenable to highthroughput screening of chemical and rnai libraries rely on 4 main biochemical events induced during programmed cell death: mitochondrial membrane depolarization, caspase activation, chromatin condensation, and cytosolic release of Dna fragments ( Table 1) . Dna-specific dyes such as hoechst 33342 4 and acridine orange 5 are toxic to cells, prohibiting their use for studying apoptosis in real time. similarly, mitotracker probes 6 covalently label mitochondria and potentially interfere with the apoptotic process, precluding their use for real-time studies. enzyme-linked immunosorbent assay (elisa)-based methods to quantify the cytosolic release of Dna fragments 7 or caspase activation 8 suffer from necessary washing steps, incompatible with real-time kinetics. Washing steps are also required for assays relying on the PhiPhilux 9 and flica 10 fluorogenic substrates. similarly, cell lysis is necessary when employing the caspase-glo assay 11 or fluorogenic substrates such as DeVD-amc. 12 finally, several published caspase activation assays rely on the transfection of the cell line of interest with a recombinant caspase substrate. 13, 14 severe drawbacks of this approach include lack of versatility because the cells of interest need to be transfected prior to performing the assay and potentially lack of physiological relevance due to the transformation of the original cell line. to date, no method amenable to microplates provides access to real-time kinetics of induction of apoptosis without requiring prior transfection of the cells of interest with a recombinant caspase substrate ( Table 1) .
Because of their central role as death effector mediators, activation of group ii caspases constitutes an attractive biochemical event to follow for the monitoring of apoptosis. however, caspase activation is a transient event in a cell, and cells within any given population are heterogeneous and undergo apoptosis at different rates. it is therefore essential for a high-content screening assay monitoring apoptosis to allow multiple measurements in the same well over time. for this reason, we sought to employ a live and homogeneous assay, compatible with the assessment of real-time kinetics of apoptosis in highdensity format. the caspase-activated DeVD-nucView488 (DnV) fluorogenic substrate appears to be compatible with such requirements 15 ; this cell-permeable substrate consists of a derivative of the Dna intercalating dye thiazole orange attached to the highly negatively charged DeVD peptide. 15 Presumably, the negative charges provided by the DeVD peptide prevent binding of the nucView488 dye moiety to Dna in healthy cells where caspase activity is low. in contrast, in the cytoplasm of cells undergoing apoptosis, the DeVD sequence is thought to be cleaved by caspase 3-and potentially by other members of group ii caspases. cleavage of the DeVD peptide releases a functional dye able to bind to Dna and to fluoresce when excited at 488 nm ( Fig. 1) . the dye is not fluorescent until it binds to nucleic acids such as Dna in cell nuclei 15 ; its fluorescence signal remains associated with Dna and is therefore retained within the cell. in addition, the DnV substrate does not appear to cause any toxicity or to interfere with the progression of apoptosis. 15 consequently, the DnV substrate appears especially useful for live-cell monitoring of apoptosis. however, to date, reported uses of the DnV substrate are limited to single time point measurements using fluorescence-activated cell sorting (facs) analysis 16 or fluorescence microscopy. 17, 18 on the basis of the characteristics of the DnV substrate, we speculated that we could adapt its use to high-density microplates and to live imaging of apoptosis in high-content screens.
in this article, we report the adaptation, optimization, and validation of the use of the DnV fluorogenic substrate as a homogeneous, live assay for monitoring real-time kinetics of apoptosis in high-density format. We demonstrate that our optimized method enables real-time screening of chemical and rnai libraries for the rapid identification of both early and late modulators of apoptosis.
MATERIALS AND METHODS

Reagents
the DnV substrate was purchased from Biotium, inc. (hayward, ca). Dulbecco's modified eagle's medium (Dmem), rPmi1640, glutamine, penicillin, streptomycin, optimem, phosphate-buffered saline without mg 2+ and ca 2+ (PBs), lipofectamine rnaimaX, lipofectamine 2000, hoechst 33342, rhodamine phalloidin, alexa fluor 633 phalloidin, and goat antirabbit igg antibody conjugated with alexa fluor 488 were purchased from invitrogen life science (carlsbad, ca). rabbit anti-Bcl-Xl polyclonal antibody was purchased from Pharmingen (san Diego, ca). fetal bovine serum (fBs) was obtained from omega scientific (tarzana, ca). Paraformaldehyde was purchased from electron microscopy science (hatfield, Pa). erlotinib (tarceva) was purchased from lc laboratories (Woburn, ma). Doxorubicin, etoposide, triton X-100, and green fluorescent protein (gfP) sirna were purchased from sigma-aldrich co. (saint louis, mo). Z-VaD-fmk (carbobenzoxy-valyl-alanyl-aspartyl-[o-methyl]-fluoromethylketone) was purchased from Biomol international (Butler Pike, Pa). allstars hs cell Death control sirna pool was purchased from Qiagen, inc. (germatown, mD). DraQ5 is manufactured by Biostatus limited (leicestershire, Uk) and distributed in the United states by axxora llc (san Diego, ca).
hela-Bcl-Xl cells overexpressing the antiapoptotic protein Bcl-Xl were generated in the laboratory of Dr. Xiaodong Wang (University of texas southwestern medical center at Dallas, Dallas, tX) by stable transfection as previously described, as well as control hela-empty cells transfected with an empty control vector. 19 hela-empty and hela-Bcl-Xl cells were cultured in Dmem supplemented with 10% fBs, 1 mm glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. non-small cell lung cancer cell lines h3255 and h2030 were obtained from Dr. romel somwar (memorial sloan-kettering cancer center, new York, nY) and were cultured in rmPi1640 supplemented with 10% fBs, 1 mm glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. all cells were grown under a humidifed atmosphere of 5% co 2 -95% air at 37 °c.
Instrumentation for cell imaging
the caspase activation assay was performed on a fully automated linear track robotic platform (crs f3 robot system, thermo fisher scientific, Waltham, ma) with integrated peripherals for plate handling, liquid dispensing, and microscopy imaging. images were acquired with an in cell analyzer 1000 epifluorescence automated microscope (inca1000) (ge healthcare, Piscataway, nJ) equipped with a 10× objective. to image the DnV probe signal, s475/20× excitation filter (475 nm excitation peak; ±20 nm bandpass), hQ535/50 emission filter (535 nm emission peak; ±50 nm bandpass), and Q505lP dichroic were used, exposing fields for 200 ms for the green channel and 60 ms for brightfield image. imaging for hoechst staining of nuclei count was performed on the same platform, using a D360/40 excitation filter (360 nm excitation peak; ±40 nm bandpass), hQ535/50 emission filter (535 nm emission peak; ±50 nm bandpass), and Q505lP dichroic, and exposing fields for 200 ms in the blue channel. imaging for DraQ5 staining of nuclei count was performed on the same platform, using hQ622/36 excitation filter (622 nm excitation peak; ±36 nm bandpass), hQ700/75 emission filter (700 nm emission peak; ±75 nm bandpass), and 51008bs dichroic, and exposing fields for 200 ms in the blue channel. in all cases, 4 image fields were collected per well, and image analysis was conducted with the in cell Developer 1.7 software (ge healthcare) using custom-developed analysis modules. the analysis modules were developed as follows. the analysis module for the nucView488 signal conducts object segmentation in the green channel and quantifies the number of objects and the intensity per object, and data are reported as the sum of the fluorescence intensity for all imaged objects in the 4 fields as relative fluorescence units. the analysis module used for nuclei count performs object segmentation in the blue channel to automatically define and count the number of nuclei. Data are reported as the sum of imaged nuclei. confocal microscopy imaging was performed using an in cell analyzer 3000 automated confocal microscope (inca3000). this laser-scanning confocal imager comprises 2 laser light sources, 3 excitation lines, and 3 highly sensitive 12-bit ccD cameras allowing simultaneous imaging of 3 fluorophores with continuous laser-based autofocus. image acquisition was performed at the following excitation/emission wavelengths (λexcitation, nm/λemission, nm): 364/450, 488/535, and 633/695. images were captured with an exposure time of 1.5 ms, collecting 4 images per well using a 40× objective. Data were acquired using the raven 1.0 software (ge healthcare). image processing was performed using the in cell Developer toolbox 1.7 software.
Immunostaining of Bcl-XL antiapoptotic protein in HeLa-Empty and HeLa-Bcl-XL cells
hela-empty and hela-Bcl-Xl cell suspensions were dispensed into a 384-well assay plate (corning 3985, corning, inc., corning, nY) at a cell seeding density of 1000 cells per well in 45 µl medium using a multidrop 384 dispenser (thermo electron corporation, Waltham, ma). at 24 h after cell seeding, cells were pretreated with 40 µm Z-VaD-fmk in PBs or with control PBs. one hour later, cells were treated with 25 µm doxorubicin. at 48 h posttreatment, cells were fixed for 20 min using 4% (v/v) paraformaldehyde, washed with PBs, and permeabilized with 0.1% (v/v) triton X-100 in PBs for 15 min. after a wash in PBs, cells were incubated for 30 min with 5% (v/v) fBs in PBs. Bcl-Xl immunostaining was performed using a rabbit anti-Bcl-Xl polyclonal antibody and an antirabbit secondary antibody conjugated with alexa fluor 488. actin staining was performed with rhodamine phalloidin at a final dilution of 1/40 for 20 min. after 3 washes in PBs, the cells nuclei were stained with 40 µg/ml hoechst 33342 for 15 min, and 50 µl PBs was added to the wells after a final wash in PBs. imaging was performed using the inca1000 as described above.
Evaluation and colocalization of the NucView488 dye
hela-empty and hela-Bcl-Xl cell suspensions were seeded as previously described. at 24 h postseeding, 12-point doubling dilutions of etoposide in 10% (v/v) Dmso ranging from 0.5 µm to 1 mm were prepared in a polypropylene 384well microplate (aBgene, rockford, il), and 5 µl of each dilution was transferred to the assay plate using a PP-384-m Personal Pipettor (apricot Designs, monrovia, ca) to reach a final concentration of etoposide ranging from 0.05 to 100 µm in 1% Dmso (v/v), after which 5 µl of 5 µm DnV substrate solution in PBs was dispensed to the assay plates using a flexDrop iV (Perkinelmer, Waltham, ma). the assay plate was incubated for 72 h in an automated steri-cult incubator (thermo scientific, inc., Waltham, ma). cells were then fixed and stained with alexa fluor 633 phalloidin and hoechst 33342 according to the protocol previously described. images were acquired on the inca3000 as described above.
Automated imaging and quantification of caspase activation using the DNV fluorogenic substrate
cells (1000 per well for hela-empty and hela-Bcl-Xl; 2000 per well for h3255 and h2030) were dispensed in 45 µl medium in 384-well microplates (corning 3985) using the multidrop 384 dispenser and incubated in the steri-cult incubator. if pretreatment with Z-VaD-fmk pan-caspase inhibitor was tested, it was performed 1 h prior to treatment at a final concentration of 40 µm in 1% Dmso (v/v). transfection with sirnas or treatment with small molecule was performed 24 h after cell seeding by transferring sirna complexes or drug dilutions from a polypropylene 384-well source plate to the 384-well assay plates using the PP-384-m Personal Pipettor, after which 5 µl of 5 µm DnV solution in PBs was dispensed to the assay plates using the flexDrop iV. images were acquired on the inca1000 as described above, over a time course of up to 96 h post-DnV substrate addition. each assay condition was performed in duplicate, and reported data correspond to the average of 2 wells, except for rna knockdown experiments, which were performed in quadruplicate; reported data in that case correspond to the average of 4 wells, and error bars represent the standard deviation of the data obtained in quadruplicate. for comparison of the nucView488 signal with nuclei count, DraQ5 live staining of nuclei was performed after the last time point by adding DraQ5 to the cells diluted in PBs to reach a final concentration of 2.5 µm. images were acquired on the inca1000 as described above.
siRNA transfection
cells were seeded in 384-well microplates as described above, and transfection with gfP or cell death sirna pool was conducted 24 h after cell seeding. transfection of cell death sirna pool in hela-empty cells was performed using 0.025 µl lipofectamine rnai max per well; sirna transfection in hela-empty and hela-Bcl-Xl cells was performed using 0.075 µl lipofectamine 2000 per well. sirnas were preincubated with the transfection reagent for 20 min at room temperature in optimem, and 10 µl of the complex was transferred to the assay plates. the sirna final concentration was 100 nm for all transfections. following transfection, 5 µl DnV substrate solution in PBs was added to each well using the flexDrop iV, and automated imaging and quantification of caspase activation were performed as described above 48 h posttransfection.
Assessment of the effect of the DNV substrate on the proliferation of HeLa cells
hela-empty and hela-Bcl-Xl cell suspensions were seeded as described above; at 24 h postseeding, 12-point doubling dilutions of the DnV substrate in 10% (v/v) Dmso ranging from 0.5 µm to 1 mm were prepared in a polypropylene 384-well microplate, and 5 µl of each dilution was transferred to the assay plates to reach a final concentration of DnV substrate ranging from 0.05 to 100 µm in 1% Dmso (v/v). the assay plates were incubated for 24, 48, 72, and 96 h in the stericult incubator. at each time point, cells were fixed for 20 min using 4% (v/v) paraformaldehyde and washed with PBs, and the cell nuclei were stained with 40 µg/ml hoechst 33342 for 15 min. images were acquired on the inca1000 as described above. each assay condition was performed in duplicate, and reported data correspond to the average of 2 wells.
Assessment of the stability of the DNV substrate signal
twelve-point doubling dilutions of etoposide in 10% (v/v) Dmso ranging from 0.05 to 100 µm were prepared in a polypropylene 384-well microplate, and 5 µl of each dilution was transferred to 384-well assay plates to reach a final concentration of etoposide ranging from 0.005 to 10 µm in 1% Dmso (v/v). hela-empty and hela-Bcl-Xl cell suspensions were dispensed into the assay plates at a cell seeding density of 1000 cells per well in 45 µl medium using the multidrop 384 dispenser. for each cell line, after the initial cell seeding, cells were dispensed 3, 6, 12, and 24 h later into 4 plates corresponding to the 3-, 6-, 12-, and 24-h time points after preparation of the DnV substrate solution (5 µm in PBs, protected from the light). the assay plates were incubated in the automated stericult incubator, and 24 h after cell seeding, 5 µl of the DnV substrate was dispensed into each plate using the flexDrop iV. automated imaging and quantification of caspase activation for each plate 24, 48, 72, and 96 h after substrate addition were performed as described above. each assay condition was performed in duplicate, and reported data correspond to the average of 2 wells.
RESULTS
Evaluation of apoptosis-resistant HeLa-Bcl-XL cells
for the purpose of evaluating, optimizing, and validating the use of the DnV substrate for real-time monitoring of apoptosis, we took advantage of a well-described hela cell line stably transfected with the antiapoptotic protein Bcl-Xl (hela-Bcl-Xl), which is resistant to apoptosis. control hela cells were transfected with the vector only (hela-empty). 19 We confirmed by immunostaining that hela-Bcl-Xl cells overexpress Bcl-Xl compared to hela-empty cells ( Fig. 2A,B) . as expected, the signal corresponding to the immunostaining of Bcl-Xl in the green channel is practically nonexistent for hela-empty cells ( Fig. 2A) , whereas green staining is intense for almost all imaged hela-Bcl-Xl cells (Fig. 2B) . after exposure for 48 h to doxorubicin, most hela-empty apoptosissensitive cells have been decimated; interestingly, surviving hela-empty cells were found to overexpress Bcl-Xl, as observed in the green channel ( Fig. 2C) , highlighting the heterogeneity of Bcl-Xl expression in the cell population. in contrast, most of the hela-Bcl-Xl cells were resistant to exposure to 25 µm doxorubicin for 48 h (Fig. 2D) . altogether, these results validate hela-Bcl-Xl cells as a model of apoptosisresistant cells. as a control, we employed the broad-spectrum caspase inhibitor Z-VaD-fmk (carbobenzoxy-valyl-alanylaspartyl-[o-methyl]-fluoromethylketone). Z-VaD-fmk is a cell-permeant pan-caspase inhibitor that irreversibly binds to the catalytic site of caspase proteases and can inhibit induction of apoptosis. 20 When pretreated with the pan-caspase inhibitor Z-VaD-fmk, hela-Bcl-Xl cells were in part protected from apoptosis, as attested by the presence of a greater number of healthy cells compared to no pretreatment ( Fig. 2E,C) . Pretreatment with the caspase inhibitor had little effect on the apoptosis-resistant cells hela-Bcl-Xl, as expected (Fig. 2F) . the hela-empty/hela-Bcl-Xl isogenic pair is used in this study as a main tool for validating our live caspase activation monitoring method.
Imaging of caspase activation using the DNV substrate
the DnV substrate is reported to stain the nucleus of apoptotic cells after cleavage by activated caspase 3 in the cytoplasm. 15 to confirm this hypothesis, we performed a triple staining with hoechst, DnV, and phalloidin rhodamine of hela-empty cells pretreated with 10 µm doxorubicin in a 384-well microplate. imaging on an automated confocal microscope reveals that the nucView488 signal visualized in the green channel is colocalized with hoechst staining of Dna visualized in the blue channel (Fig. 3) . the overlay of the red channel corresponding to rhodamine staining of actin filaments with the blue and green channel shows that nucView488-positive cells have a condensed nucleus and a collapsed cytoskeleton. in addition, the intensely bright and condensed hoechst staining of nucView488-positive cells is indicative of chromatin condensation ( Fig. 3) . these observations are in agreement with the morphological features of apoptotic cells: chromatin condensation, nuclear and cell shrinkage, nuclear fragmentation, membrane blebbing, and formation of apoptotic bodies. altogether, our results seem to suggest that the DnV substrate specifically stains the nucleus of apoptotic cells after treatment with doxorubicin.
We then investigated the feasibility of an automated caspase activation assay relying on the DnV substrate. hela-empty cells transfected in a 384-well microplate format with a cell death sirna pool targeting human genes essential for survival were imaged on an automated epifluorescence microscope. intense staining in the green channel can be observed for a majority of the cells 72 h posttransfection (Fig. 4D) . this result is in sharp contrast with control hela-empty cells treated with the cell death sirna pool in the absence of transfection reagent, for which almost no signal can be detected (Fig. 4A) . Brightfield imaging of the same field reveals a sparse population of cells with a shrunken cytoplasm for the transfected cells ( Fig. 4E) , whereas the control cells are present in large number and have a healthy morphology (Fig. 4B) . our results indicate that the DnV substrate specifically stains apoptotic cells after transfection with sirnas targeting genes essential for survival. for the purpose of automatically quantifying the nucView488 signal, we developed an image analysis algorithm based on object segmentation. our custom-developed analysis module can accurately recognize the stained objects in the green channel, as shown in Figure 4F . the software then quantifies the number of objects and the intensity per object for each of the fields imaged. the data can also be summed and averaged per well. all following quantifications described in this article rely on this image analysis module.
Optimization and validation of a high-content assay for monitoring live caspase activation based on the DNV substrate
to assess the cytotoxic effects of the DnV substrate over the course of a typical cell-based screen, we treated hela-empty and hela-Bcl-Xl cells with 12 doubling dilutions of the DnV substrate ranging from 0.05 to 100 µm for 96 h and performed an automated nuclei count of the treated cells at 24, 48, 72, and 96 h posttreatment. no significant effect on the proliferation of hela-empty or hela-Bcl-Xl cells was observed with up to 100 µm substrate for as long as 96 h treatment, confirming that the DnV substrate is not toxic (Fig. 5A,B) . to identify the optimal concentration of DnV substrate to use in high-content screens, we performed titration experiments in a 384-well format in the context of both a small molecule and a sirna screen. We tested 3 concentrations of DnV substrate-0.1, 0.5, and 1 µm-based on the recommendations from the supplier (1 µm). as expected, the signal obtained with hela-empty and hela-Bcl-Xl cells treated with doxorubicin was higher than for cells treated with the Dmso control (Fig. 5C) . not surprisingly, the signal obtained with hela-Bcl-Xl cells resistant to apoptosis was consistently lower compared to hela-empty cells. Using 0.5 µm substrate provided an 80 to 1 signal-to-noise ratio between doxorubicin and Dmso-treated hela-empty cells. interestingly, we observed a 10 to 1 signalto-noise ratio between doxorubicin-treated hela-empty cells and doxorubicin-treated hela-Bcl-Xl cells, in agreement with the level of overexpression of Bcl-Xl protein in hela-Bcl-Xl cells compared to hela-empty cells. our results strongly suggest that the DnV substrate accurately reflects the level of apoptosis for the imaged cells and that our custom image analysis module correctly quantitates the nucView488 signal for the imaged well. to test the automated quantification of apoptosis induced by sirna knockdown in the context of an rna interference screen, we performed a pilot experiment using a cell death sirna pool targeting human genes essential to survival. controls consisted of cells treated with the cell death sirna pool in the absence of transfection reagent and of cells transfected with untargeted control sirna. significant caspase activation was observed and quantified for both helaempty and hela-Bcl-Xl cells transfected with the cell death sirna pool compared to the untargeted and mock transfection controls (Fig. 5D) . as expected, the nucView488 signal induced by the cell death sirna pool was significantly lower for the hela-Bcl-Xl apoptosis-resistant cells compared to hela-empty cells. Using 0.5 µm substrate provided an optimal signal-to-noise ratio of 8 to 1 between the 2 cell lines. altogether, our observations suggest that the optimal concentration of DnV substrate to use with hela-empty and hela-Bcl-Xl cells is 0.5 µm.
to test the specificity of the caspase activation signal obtained with the DnV substrate, we employed the pan-caspase inhibitor Z-VaD-fmk. hela-empty cells treated with doxorubicin and monitored using the DnV substrate demonstrated timedependent caspase activation over a 72-h period, with a peak at 66 h (Fig. 2G) . in contrast, the nucView488 signal was close to nonexistent for cells treated with control Dmso. importantly, hela-empty cells pretreated with the pan-caspase inhibitor Z-VaD-fmk had their caspase activation signal reduced by 5-fold ( Fig. 2G) , demonstrating that the nucView488 signal that we imaged and quantified specifically reflects the status of caspase activation in the imaged cells. in hela-Bcl-Xl apoptosis-resistant cells, the caspase activation signal induced by doxorubicin was 9-fold lower compared to hela-empty cells (Fig. 2H) , consistent with our previous observation (Fig. 5C) . as expected, Z-VaD-fmk also reduced the intensity of caspase activation in these cells (Fig. 2H) .
an automated screen campaign involves predispensing and storing reagents on deck over the entire course of the screen; therefore, the stability of the DnV substrate in the conditions of screening is an important factor to assess. for this reason, we conducted an experiment where we performed live monitoring of caspase activation in hela-empty and hela-Bcl-Xl cells treated with etoposide. the DnV substrate was stored on our automated platform for 0, 3, 6, 12, or 24 h in the conditions of screening before being dispensed into the wells. after a 48-and 72-h incubation with etoposide or Dmso control, we performed imaging and quantification of the nucView488 signal on an automated epifluorescence microscope. importantly, we found that the high signal induced by etoposide on helaempty cells after a 72-h incubation remained practically constant for up to 12 h storage (Fig. 6A) . furthermore, the low signal induced by control Dmso remained consistently low for up to 24 h storage ( Fig. 6A) , as well as the low signal observed with hela-Bcl-Xl apoptosis-resistant cells (Fig. 6B) , as expected. this important result demonstrates that storage of the diluted substrate in the conditions of screening did not alter its specificity for apoptic cells and did not induce any increase in background noise. We conclude that a batch of DnV reagent can be used for dispensing in the conditions of screening for up to 12 h continuously.
Validation of the newly developed method for live monitoring of real-time kinetics of caspase activation in high-content screens
We further validated our newly developed method for monitoring real-time kinetics of caspase activation using the well-characterized pair of non-small cell lung cancer (nsclc) cell lines: h3255 and h2030 cell lines. 21 Both lines were derived from patients with nsclc arising from oncogenic epidermal growth factor receptor (egfr) or kras. h3255 cells harbor the l858r mutation in the egfr gene and are sensitive to the egfr tyrosine kinase inhibitor erlotinib (tarceva). in contrast, h2030 cells express wild-type egfr and mutated kras and are refractory to erlotinib. this pair of nsclc cell lines therefore provides a good platform for validating our newly developed method to quantify apoptosis in high-content screens. We monitored the real-time kinetics of caspase activation induced by concentrations of erlotinib ranging from 0.01 to 10 µm in both cell lines, imaging the cells at regular time intervals after treatment over a course of 96 h (Fig. 7) . We found that we could visualize ( Fig. 7A) quantify (Fig. 7E) erlotinib-induced caspase activation in h3255 erlotinib-sensitive cells as early as 18 h posttreatment, gradually increasing over time to reach a plateau at 48 and 63 h and decreasing from 63 h to 96 h posttreatment. in addition, erlotinib-induced caspase activation in these cells was dose dependent at any of the imaged time points (Fig. 7E) . in contrast, monitoring of nucView488 signal induced by erlotinib in the erlotinib-refractory h2030 cells revealed low caspase activation at any time point and for any of the tested concentrations, in agreement with their chemosensitivity profile (Fig. 7B,F) . these results were supported by imaging of the nuclei after a 96-h treatment: few nuclei could be visualized for h3255 cells treated with 0.01 and 0.5 µm erlotinib, in sharp contrast with h2030 cells (Fig. 7C,D) . 
DISCUSSION
apoptosis is central to a number of pathological proliferative disorders, including cancer. therefore, the ability to monitor apoptosis in high-content screens is highly sought for the discovery of drugs in a wide range of therapeutic areas. current methods to follow apoptosis rely on quantifying caspase activation, given the central role of this class of enzymes as death effector molecules. however, direct monitoring of caspase activation in live cells in the context of a high-content screen is a difficult task for 2 reasons. first, cell death signaling in response to proapoptotic stimuli is limited in time, and cultured cells are typically not synchronized. therefore, caspase activation in cultured cells is a transient and heterogeneous event. second, technical hurdles have so far limited the monitoring of caspase activation to single time point measurements. for these combined reasons, to our knowledge, no method currently exists that allows continuous, live monitoring of caspase activation in high-content screens. the requirements for such an assay are (1) amenable to high-density format, (2) live and continuous, (3) nontoxic and not interfering with apoptosis, and (4) versatile. a previous report suggests that the DnV substrate meets the requirements for such an assay, 15 but reported uses of the DnV substrate are limited so far to single time point measurements using facs analysis 16 or fluorescence microscopy. 17, 18 for this reason, we sought to evaluate and optimize the use of the DnV substrate as a novel method to monitor the real-time kinetics of caspase activation in high-content screens.
our confocal imaging experiments confirm that following DnV addition, the nucView488 signal is confined to the nucleus or the perinuclear region of cells undergoing apoptosis (Fig. 3) . together with data reported by others, 15 these results suggest that the DnV substrate is nonfluorescent until it is cleaved by activated effector caspases, thereby allowing the nucView488 substrate to stain the nuclei of apoptotic cells. Because the DeVD peptide corresponds to the optimal substrate sequence for both caspase 3 and caspase 7, it is therefore probably cleaved by both enzymes. 22 this sequence could also potentially be cleaved at a slower rate by other members of the group ii family of caspases with slightly different specificities. 22 the assay requires a unique addition of DnV substrate, in the absence of any washing step. in addition, we show that the DnV substrate is not toxic to hela cells (Fig. 5A,B) . altogether, these observations confirm that a method based on the use of the DnV substrate could allow continuous monitoring of caspase activation. after optimizing the substrate concentration with hela cells (Fig. 5C,D) , we sought to validate the use of the DnV substrate for live monitoring of apoptosis in high-content screens. We demonstrated that the nucView488 signal observed in the green channel can be imaged in highdensity format on a robotic platform equipped with an automated epifluorescence microscope. imaging of the same well can be performed as many times as needed over the course of a screen, and the obtained images can easily be processed by automated analysis software and quantified ( Figs. 4 and 7) . Data are collected at the single-cell level, allowing us to study heterogeneous populations of cells ( Fig. 4) . We show that a high signal is observed and quantified when hela-empty cells are treated with doxorubicin or etoposide, both drugs known to induce apoptosis in cancer cell lines (Figs. 2, 3, 5, and 6) . however, pretreatment with a pan-caspase inhibitor can antagonize this high signal, demonstrating the specificity of the signal imaged using the DnV substrate (Fig. 2) . of note, we noticed that control cells treated with Dmso exhibit a strong nuclear staining using hoechst 33342 (Fig. 2B) , whereas the nuclear staining for cells pretreated with doxorubicin and stained with hoechst in the same conditions is very weak (Fig.  2D,F) . it is likely that we are observing the quenching of hoechst fluorescence by energy transfer to doxorubicin, as the maximum emission wavelength of hoechst bound to Dna is 458 nm, which is near the maximum excitation wavelength of doxorubicin bound to Dna (473 nm). 23 this probably leads to energy transfer between the 2 dyes, which results in the quenching of hoechst fluorescence as previously observed. 24, 25 nuclei staining with an alternative dye such as DraQ5 is therefore recommended when performing nuclei count after doxorubicin treatment. in addition, in hela-Bcl-Xl overexpressing the antiapoptotic protein Bcl-Xl, a much lower nucView488 signal was observed when those cells were treated with doxorubicin ( Figs. 2 and 5C) . similarly, transfection of hela-empty cells with an sirna pool targeting genes essential for cell survival resulted in a significant increase in nucView488 signal compared to a no-sirna control or transfection with an untargeted sirna (Fig. 5D) ; in hela-Bcl-Xl cells, the quantified nucView488 signal was dramatically reduced compared to hela-empty cells. altogether, our results validate the new method we have developed, in that we could reliably track and quantify apoptosis induced by small molecules or rna interference over time, as well as its inhibition by caspase inhibition or by overexpression of the antiapoptotic Bcl-Xl protein. in contrast to previous uses of the DnV substrate, we demonstrate that our method allows monitoring of apoptosis for the same cell population at multiple time points. of note, the fact that our method could be employed to either track apoptosis induced by a small molecule or by knockdown of gene expression demonstrates its great versatility. for further validation, we sought to test our method in a different cell system; we used for this purpose the welldescribed nsclc cell lines h3255 and h2030. 21 We could precisely monitor the real-time kinetics of caspase activation induced by erlotinib in the erlotinib-sensitive cell line h3255. as expected, the strong caspase activation induced by erlotinib in this cell line was time and dose dependent (Fig. 7A,E) . in contrast, only low levels of caspase activation could be detected in the erlotinib-refractory h2030 cell line at any time point or tested concentration (Fig. 7B,F) . these results strongly validate our method and demonstrate its flexibility, in that we could easily employ our newly developed assay with different cell lines without any prior cell engineering or any dedicated optimization for the new lines. in addition, our live, real-time method allowed us to take multiple snapshots of the cells during the same experiment. this result is important because it demonstrates that our method can detect early as well as late inducers of apoptosis in the same screen. furthermore, our method allows for a high-throughput screen to be performed without compromising plate-to-plate variability. on the basis of our experience and according to simulations using the Polara  scheduling software, we estimate that a throughput of a hundred 384-well plates a week can be achieved by staggering plates. this estimation is based on a fully automated screen with 3 readouts every 24 h over a course of 72 h, where all plates are read at exact intervals of 24 h. this throughput allows for the screening of roughly 35,000 compounds a week. We have performed such a screen with a total of 28 plates, and we will be submitting the results in a manuscript shortly.
in summary, our method meets all the requirements for a live assay aimed at quantifying apoptosis in high-density format. We conclude that our method allows for the first time the monitoring of real-time kinetics of apoptosis in high-content screens and could be used in combination with other readouts as a multiplexed assay for cell death. We expect that the flexibility of our method will allow us to dissect apoptosis signaling pathways using both chemical and functional genomics, thereby enabling the rapid identification of novel modulators of apoptosis.
